A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Leading drugmaker Amgen could ...

It recently reported strong phase 3 results for an investigational eczema treatment, rocatinlimab. A strong lineup and ...

Another important candidate, rocatinlimab is being evaluated in phase III studies for atopic dermatitis and prurigo nodularis. Several data readouts are expected over the next six to 12 months ...

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...